-

Fresenius Kabi Introduces KabiCare Nutrition Resources for U.S. Parenteral Nutrition Products

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today it has introduced KabiCare Nutrition Resources in the United States as part of its KabiCare patient support program. The KabiCare Nutrition Resources program provides support for insurance reimbursement questions including a helpline staffed by experts to provide billing and coding support, insurance support such as benefit investigation, prior authorization and claims appeals. More information about KabiCare Nutrition Resources can be found at kabicare.us.

“Navigating the complexity of health insurance to provide access to critical parenteral nutrition products continues to be a challenge for some patients,” said Tom Tsilipetros, senior director, Market Access, at Fresenius Kabi USA. ”As a leader in parenteral nutrition, Fresenius Kabi’s goal with the KabiCare Nutrition Resources program in the U.S. is to help assure patients receive their care and parenteral nutrition products in as timely a manner, and as seamlessly, as possible.”

About KabiCare, a Patient Support Program

Fresenius Kabi created KabiCare, a Patient Support Program, to support patient access to products across numerous therapeutic areas. KabiCare provides a patient-centric approach which includes support and resources for eligible patients, caregivers, and health care providers throughout the treatment journey. For eligible patients, support may include navigating complex insurance processes as well as financial assistance. For additional information, please call 1-833-KABICARE or visit kabicare.us.

About Fresenius Kabi

Fresenius Kabi (www.fresenius-kabi.com/us) is a global health care company that specializes in medicines and technologies for infusion, transfusion, and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany. To learn about U.S. career opportunities at Fresenius Kabi, visit us at www.fresenius-kabi.com/us/join-us and follow us on LinkedIn.

Contacts

Matt Kuhn
(847) 220-3033
matt.kuhn@fresenius-kabi.com

Fresenius Kabi


Release Versions

Contacts

Matt Kuhn
(847) 220-3033
matt.kuhn@fresenius-kabi.com

Social Media Profiles
More News From Fresenius Kabi

Fresenius Kabi Expands Operating Room Portfolio with New Simplist® Prefilled Syringes

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, part of the global healthcare company Fresenius, and a leading provider of essential medicines and medical technologies, announced today it has introduced two new products in its Simplist® portfolio of ready-to-administer prefilled syringes: Simplist® Ephedrine Sulfate Injection, USP and Simplist® Succinylcholine Chloride Injection, USP. Both medications are used in anesthesia and critical care, and their introduction extends the Simplist line...

Fresenius Kabi Introduces Dalbavancin for Injection (for single-dose regimen use only)

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, part of the global healthcare company Fresenius, and a leading provider of essential medicines and medical technologies, announced today it has introduced Dalbavancin for Injection (for single-dose regimen use only), which is indicated for the treatment of adult and pediatric patients with acute bacterial skin and skin structure infections caused by designated susceptible strains of Gram-positive microorganisms. It is available in 500 mg vials...

Fresenius Kabi’s Adaptive Nomogram used on Aurora Xi Plasmapheresis System Now Operating Nationwide at BioLife Plasma Centers

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, part of the global healthcare company Fresenius, and a leading provider of essential medicines and medical technologies, announced today the successful completion of the U.S. rollout of the Adaptive Nomogram technology used on its Aurora Xi Plasmapheresis System across BioLife Plasma Services’ network of plasma donation centers. The implementation, which began in March 2025 in a phased approach, has been completed ahead of schedule, marking a...
Back to Newsroom